In February 2021, we organised our Annual Networking Event, attended by industry, our key partners, and members organisations, to discuss our plans and future collaboration opportunities. We looked back at EMSP’s main achievements in 2020 and outlined our common priorities for 2021 and beyond.

Work with the European Medicines Agency / EUnetHTA

EMSP is a member of the Patient and Consumer Working Party and the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). By being an active member within EMA, EMSP is looking to extend an intensive cooperation between MS patients and the EMA to involve people with MS in all possible procedures within EMA. Patients’ contribution is particularly important for pharmacovigilance, e.g., adverse drug reaction reporting, as well as encouraging national authorities to implement all rules of the Pharmacovigilance Directive. Another major issue in which EMSP is involved is risk/benefit assessment and the communication towards patients on this issue.

EMSP is a collaborating partner of EUnetHTA, a EU Commission-established initiative to create an effective and sustainable network for Health Technology Assessment (HTA) across Europe. EMSP provides support in terms of effectiveness of HTA models, and strives for better patient involvement in processes impacting the access to treatment for people affected by MS.